Abstract:The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka in 2006 was heralded as a major breakthrough of the decade in stem cell research. The ability to reprogram human somatic cells to a pluripotent embryonic stem cell-like state through the ectopic expression of a combination of embryonic transcription factors was greeted with great excitement by scientists and bioethicists. The reprogramming technology offers the opportunity to generate patient-specific stem cells for modeling human diseases, drug development and screening, and individualized regenerative cell therapy. However, fundamental questions have been raised regarding the molecular mechanism of iPSCs generation, a process still poorly understood by scientists. The efficiency of reprogramming of iPSCs remains low due to the effect of various barriers to reprogramming. There is also the risk of chromosomal instability and oncogenic transformation associated with the use of viral vectors, such as retrovirus and lentivirus, which deliver the reprogramming transcription factors by integration in the host cell genome. These challenges can hinder the therapeutic prospects and promise of iPSCs and their clinical applications. Consequently, extensive studies have been done to elucidate the molecular mechanism of reprogramming and novel strategies have been identified which help to improve the efficiency of reprogramming methods and overcome the safety concerns linked with iPSC generation. Distinct barriers and enhancers of reprogramming have been elucidated, and non-integrating reprogramming methods have been reported. Here, we summarize the progress and the recent advances that have been made over the last 10 years in the iPSC field, with emphasis on the molecular mechanism of reprogramming, strategies to improve the efficiency of reprogramming, characteristics and limitations of iPSCs, and the progress made in the applications of iPSCs in the field of disease modelling, drug discovery and regenerative medicine. Additionally, this study appraises the role of genomic editing technology in the generation of healthy iPSCs.

Overcoming iPSC Obstacles

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Advances in Reprogramming of Peripheral Blood Cells to Induced Pluripotent Stem Cells

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Molecular Obstacles to Clinical Translation of iPSCs

Ipscs: from Bench to Clinical Bed

Progress and Bottleneck in Induced Pluripotency.

Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications

Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies

Reprogramming stem cells in regenerative medicine

Evolution of Induced Pluripotent Stem Cell Technology

Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications

The reprogramming mechanisms of induced pluripotent stem cells

Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells (iPSC) in precision cell therapies

The Research Status of Induced Pluripotent Stem Cells

Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells

Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee

Bioprocessing considerations for generation of iPSCs intended for clinical application: perspectives from the ISCT Emerging Regenerative Medicine Technology working group

Mechanism and Methods to Induce Pluripotency

Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells

[Progress and potential applications of induced pluripotent stem cell technology]